Kornimate/medical-research-clean huggingface dataset:
right ventricular function in end-stage renal disease patients

Conditions: Transthoracic Echocardiography; Hemodialysis

Summary: right ventricular (rv) dysfunction is a major cause of heart failure and mortality in end-stage renal disease (esrd) patients. the aim of the study was to evaluate the long-term impacts of different dialysis modalities on rv function assessed by conventional echocardiography in esrd patients with preserved left ventricular function. the study included 83 esrd patients grouped as follows: peritoneal dialysis (pd; n=46) and hemodialysis with brachial arterio-venous fistula (hd; n=37). conventional echocardiography including 2d and tissue doppler imaging was performed in all patients. echocardiographic parameters were compared between groups.

cardiovascular diseases (cvd) are the main causes of death in patients undergoing dialysis. right ventricular (rv) dysfunction is one of the major predictors of mortality and heart failure in this patient group. it has been shown that patients undergoing hemodialysis (hd) which is usually carried out via a surgically created arteriovenous fistula (avf) have an increased risk for pulmonary hypertension and poorer right ventricular function compared with healthy controls . however, there are few data comparing the patients undergoing hd and peritoneal dialysis (pd), in terms of echocardiographic right ventricular function. the aim of the present study was to elucidate the impact of both long term pd and hd therapy via brachial avf on rv function in patients with preserved left ventricular (lv) function. patients undergoing dialysis were grouped as follows: 46 patients on pd and 37 patients on hd with brachial avf. all of the study patients underwent transthoracic echocardiography. left and right ventricular parameters were compared between two groups.

Eligibility criteria:
inclusion criteria: * end-stage renal disease patients on a regular dialysis program * being on dialysis at least 6 months * \>18 years old exclusion criteria: * ischemic heart disease * left ventricular systolic dysfunction with an ejection fraction (ef) of less than 55 % * valvulopathy * left bundle branch block * atrial fibrilation * previous renal transplantation * chronic obstructive pulmonary disease * interstitial lung diseases * connective tissue disorders * chronic thromboembolic disease * congenital left-to-right shunt * primary pulmonary hypertension

Keywords: echocardiography hemodialysis peritoneal dialysis right ventricle
safety & efficacy of nab001 in the treatment of mild to moderate onychomycosis of the toenails

Conditions: Onychomycosis

Summary: the objectives of this study are to assess the safety of nab001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of nab001 to vehicle alone at the end of the study (week 56) after treating for 52 weeks.


Eligibility criteria:
inclusion criteria: * mild to moderate fungal infection of the toenail as assessed by study doctor * koh positive \& dermatophyte culture positive at visit 1 * good general health as assessed by the study doctor exclusion criteria: * severe fungal toenail infection * prior use of antifungal drugs (wash-out allowed, duration varies on class) * significant confounding conditions as assessed by study doctor * pregnancy/lactation * must forego nail salon procedures during study for at least \~60 weeks

Keywords: toenail fungus onychomycosis nail infection
orelabrutinib combined with obinutuzumab and lenalidomide (ogl regimen) as first-line treatment for marginal zone lymphoma.

Conditions: Marginal Zone Lymphoma

Summary: this is a multicenter prospective single arm phase ii study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. the primary objective was the best complete response rate (crr).

marginal zone lymphomas (mzl) are a type of lymphoma that originates from the marginal zone tissue of the lymphoid follicles (mucosa-associated lymphoid tissue, malt), and include three subtypes: malt lymphoma, nodal mzl, and splenic mzl. the incidence of mzl is second only to diffuse large b-cell lymphoma (dlbcl) and follicular lymphoma (fl), accounting for approximately 7.8% of all non-hodgkin lymphomas (nhl). mzl is considered an indolent lymphoma, with patients generally having a better overall survival prognosis. despite this, some patients still face the challenges of disease relapse or transformation into large cell lymphoma, leading to a poor prognosis. we conduct this prospective, phase ii, single-arm clinical study to initially explore the efficacy and safety of orelabrutinib combined with obinutuzumab and lenalidomide in patients with previously untreated marginal zone lymphoma. the patients will be treated with 6 cycles of ogl regimen. patients with cr/pr after 6 cycles of ogl treatment will be treated with 6 cycles of single-agent orelabrutinib regimen.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, either sex. * histopathologically confirmed b-cell non-hodgkin lymphoma mzl (splenic, nodal, or extra-nodal). * at least 1 measurable lesion * eligible for treatment: meets the gelf criteria, or has clinical symptoms/organ dysfunction related to the disease * patients who are not suitable for local radiotherapy or whose condition progresses after local treatment, and those not suitable for local radiotherapy include the following situations: * ann arbor non-continuous stage ii or stage iii-iv non-gastric malt and nodal mzl * smzl (splenic marginal zone lymphoma) * gastric malt with lugano stage ii2/iie/iv * ecog performance status (ps) score of 0-2. * expected survival time is ≥3 months * sign the informed consent exclusion criteria: * currently has other malignant tumors; * lymphoma involving the central nervous system * allergic to any of the study drugs; * active infection or uncontrolled hbv infection (dna\&gt;105/ml), hiv/aids, or other severe infectious diseases; * pregnant or lactating women and women of childbearing age who are unwilling to use contraception; * any other conditions deemed unsuitable for participation in this trial by the investigator.

Keywords: orelabrutinib marginal zone lymphoma obinutuzumab lenalidomide
vitamin d levels and myoma uteri

Conditions: Myoma;Uterus; Vitamin D Deficiency; Polycystic Ovary

Summary: women with at least one uterine leiomyoma and polycystic ovary syndrome over 10 mm and women with normal ultrasonographic findings were included in the study. blood samples were taken for biochemical analysis such as vitamin d, calcium, magnesium, phosphorus, thyroid stimulating hormone (tsh), hemoglobin (hb), hematocrit (htc), platelet (plt), and albumin. the study groups were compared in terms of these biochemical markers and family history of patients, daily sunshine hours, clothing preferences and education level.


Eligibility criteria:
inclusion criteria: the reproductive age women (25-50 years) with at least one 10 mm or larger diameter leiomyoma detected by transvaginal ultrasound were the study group. exclusion criteria: * patients with a history of myomectomy, * chronic systemic disease * malignancy * history of adenomyosis * women in menopause * pregnant women * vitamin d supplementation * lactation * abortion and pregnancy loss in the last 6 months * oral contraceptive / hormonal agents in the last 3 months

Keywords: 25-hydroxyvitamin d
prospective and multicenter italian registry of locally advanced-metastatic urothelial carcinoma

Conditions: Carcinoma, Urothelial

Summary: prospective and multicenter italian registry intended for naïve adult patients affected by locally advanced-metastatic urothelial carcinoma intended for systemic treatment, or for palliative or observation procedures

this is a multicentre, prospective and non-interventional study in which all patients treated according to clinical practice will be included. the registry will include all patients with metastatic urothelial carcinoma or with lymph node involvement defined as unsuitable for surgery. the study involves medical visits and clinical-radiological re-evaluations according to clinical practice. there are no additional procedures. the clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen. the participating centers were selected in such a way as to adequately represent all the different geographical areas. the duration of the study is 24 months: 12 months of enrollment plus 12 months of further follow-up.

Eligibility criteria:
inclusion criteria: * cytological and/or histological diagnosis of urothelial carcinoma or at least with one urothelial component originating from the genitourinary tract. * radiological diagnosis of metastatic or locally advanced disease inoperable * primary bladder, ureter, renal pelvis and of the urethra are included * no previous chemotherapy for advanced urothelial carcinoma or metastatic disease * age over 18 years old * ability to understand and sign the informed consent * patients for whom the clinician has opted for a therapeutic path not including active systemic treatments (iter palliative or observation) with certain diagnosis of metastatic disease * patients with lymph node extension of the disease who are not candidates to neoadjuvant treatment * any ecog ps and therapeutic management is permitted. * previous surgeries and antineoplastic treatments are permitted as long as not carried out for metastatic disease (adjuvant and/or neoadjuvant) exclusion criteria: * patients who have received previous systemic treatment for metastatic disease * patients with histological and/or cytological diagnosis without urothelial component * patients with muscle-infiltrating disease without evidence of metastatic disease * patients with non-muscle infiltrating disease without evidence of metastatic disease
predicting response to neoadjuvant chemotherapy in locally advanced breast cancer

Conditions: Locally Advanced Breast Cancer

Summary: female breast cancer is the second leading cause of global cancer incidence in 2022 and the fourth leading cause of cancer mortality worldwide. breast cancer (bc) remains the most prevalent cancer diagnosis among women; nevertheless, considerable advancements in diagnostics and treatment approaches have significantly enhanced patient outcomes. in locally advanced cases, primary systemic chemotherapy is often indicated, and the choice of treatment is influenced by the evaluation of routine prognostic and predictive factors. neoadjuvant chemotherapy (nct) has emerged as a valuable approach to enhance the quality of life ,disease-free and overall survival for early and locally advanced bc patients approximately 30% of bc cases achieve a pathological complete response (pcr) following nct. unfortunately, proper quantification of estrogen- and progesterone receptors (er and pr), human epidermal growth factor receptor-2 (her2/neu) and proliferation markers are insufficient to predict chemosensitivity of some breast tumors , so the identification of these cases during routine pathological examination of biopsy specimens could be especially useful in planning the oncotherapeutic strategy for proper patient management. cd10, has recently gained attention as an independent diagnostic and prognostic marker in various solid tumors with significant metastatic potential. this molecule has been shown to play a role in cell adhesion, migration, and extracellular matrix remodelling. a strong cd10 expression has been linked to hormone receptor negativity and her-2/neu overexpression in breast cancer. moreover, the dynamics of stromal cd10 expression undergo changes during neoadjuvant anthracycline-based chemotherapy. recent research, has presented compelling data indicating that cd10 expression may serve as a predictive marker for the impact of neoadjuvant chemotherapy in breast cancer patients.

formalin fixed paraffin embedded tissue specimen of the baseline tcnb of locally advanced breast cancer will be obtained from pathology laboratory, pathology department, assiut university. * histological diagnosis of h\&e stained sections will be confirmed. * immunohistochemical staining for cd10 . * baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records. * correlation between cd10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy.

Eligibility criteria:
inclusion criteria: * patients above 18 years * pathologically proven breast carcinoma * locally advanced breast cancer exclusion criteria: * patients below 18 years. * patients with metastatic disease * patients with second primary cancer * patients ineligible for chemotherapy

Keywords: response, neoadjuvant chemotherapy, breast cancer
safety, tolerability and pharmacokinetics of multiple doses of vak694 in atopic subjects with seasonal rhinitis

Conditions: Allergic Rhinitis

Summary: this study will assess the safety and tolerability of multiple doses of vak694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis


Eligibility criteria:
inclusion criteria: * male and female subjects between ages of 18 to 60 in good health * history of atopy for at least 2 years and positive skin prick test to ragweed allergen exclusion criteria: * history of asthma treated with corticosteroids * smokers with a smoking history of \> 10 pack/years or smoking in the past year * history of chronic obstructive pulmonary disease other protocol-defined inclusion/exclusion criteria may apply

Keywords: allergic rhinitis, atopic patients, seasonal allergy, ragweed allergy
a carbohydrate-restricted diet to reverse fatty liver in adolescents with obesity

Conditions: Non-alcoholic Fatty Liver Disease; Childhood Obesity; Insulin Resistance

Summary: the purpose of this study is to determine the effects of a low carbohydrate diet vs a low fat diet on improvement in aminotransferases, hepatic fat infiltration, markers of inflammation, insulin resistance, and body composition in obese adolescents with non-alcoholic fatty liver disease (nafld).

nafld is the most common form of liver disease in children in the united states. currently, there is no treatment for nafld. in adults, weight loss through caloric restriction is commonly recommended to improve fatty liver. weight loss is particularly difficult for children to achieve and significant caloric restriction may not be a prudent recommendation in developing children and adolescents. because of this difficulty with weight loss in children, many children go on to develop cirrhosis and eventually undergo liver transplant. data on the effectiveness of diet to reverse fatty liver and prevent progression to cirrhosis in children is urgently needed. to date, no studies have been done examining how changes in diet composition without intentional caloric restriction influences nafld in children. data from previous studies in adults support the hypothesis that consumption of lower-cho, higher-fat food sources rich in high-quality proteins and essential fatty acids has beneficial effects on metabolic health in adults without restricting calories. this study aims to test the hypothesis that a low cho higher- fat diet will induce rapid reversal of fatty liver while also depleting of total and abdominal adiposity, preserving lean mass, and reducing inflammation in adolescents with obesity and nafld.

Eligibility criteria:
inclusion criteria: * overweight/obese (bmi over the 85th percentile) male and female adolescents (age range 10-17) with elevated serum aminotransferase levels, diffusely echogenic liver via ultrasound suggestive of fatty liver, and/or prior diagnosis of nafld. participant eligibility will depend on the ability of one parent to attend the initial diet instruction and individual counseling sessions with the registered dietitian during week 2, 4 and 6 of the diet intervention. exclusion criteria: * presence of hepatic virus infections (hcv rna-polymerase chain reaction negative; hepatitis a, b, c, d, e, and g; cytomegalovirus; and epstein-barr virus), alcohol consumption, history of parenteral nutrition, and use of drugs known to induce steatosis (for example, valproate, amiodarone, or prednisone) or to affect body weight and carbohydrate metabolism. autoimmune liver disease, metabolic liver disease, and wilson's disease will be ruled out by the participants physician prior to enrollment in the study.

Keywords: childhood obesity non-alcoholic fatty liver disease insulin resistance carbohydrate-restriction
hot flashes and neurovascular function in women

Conditions: Hot Flashes; Menopause; Vasomotor System; Labile

Summary: women who experience hot flashes are at greater risk for hypertension and other cardiovascular disease. neurovascular control mechanisms are likely to play an important role in this relationship. as such, these studies are designed to provide a major step forward in understanding the link between hot flashes and neurovascular dysfunction and, by extension, cardiovascular disease in women.


Eligibility criteria:
inclusion criteria: * non-smokers. * non-obese. * have at least one ovary. * free from cardiovascular disease. * not taking medications influencing cardiovascular function. exclusion criteria: - none.

Keywords: neurovascular function autonomic function microvascular function
performance assessment of a modified daily disposable contact lens

Conditions: Refractive Errors; Myopia; Hyperopia

Summary: the purpose of this study is to compare visual acuity between two daily disposable contact lenses.

the expected duration of subject participation in the study is approximately 2 weeks, with 3 scheduled visits.

Eligibility criteria:
inclusion criteria: * able to understand and sign an approved informed consent form; * current wearer of commercial dailies total1 contact lenses in both eyes; * other protocol-specified inclusion criteria may apply. exclusion criteria: * any eye condition that contraindicates contact lens wear, as determined by the investigator; * any eye surgery that contraindicates contact lens wear, as determined by the investigator; * wears habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) * monocular (only one eye with functional vision); * other protocol-specified exclusion criteria may apply.

Keywords: contact lens vision correction visual acuity
psychosocial intervention to reduce self-stigma and improve quality of life among people with mental illness in chile

Conditions: Schizophrenia; Bipolar Disorder; Schizoaffective Disorder

Summary: the principal objective of this pilot trial is to evaluate the effectiveness of a psychosocial intervention to reduce self-stigma and improve treatment adherence and quality of life among people with a severe mental illness who attend to community mental health centers in chile. the intervention is based on recovery and narrative therapy and considers 10 group sessions, mainly with patients, but also integrating relatives and professionals in some of the activities.

it has been shown that stigma is one of the main barriers faced by individuals with mental illness, negatively impacting their service use and continuity of treatment. additionally, given its impact on self-esteem, personal empowerment, and social inclusion, stigma greatly affects the quality of life of this population. consequently, a pilot randomized controlled trial (rct) with two arms (intervention group vs. control group) was designed and implemented. participants were identified and recruited from two community mental health centers located in central chile. the intervention group, in addition to usual care, received a psychosocial intervention based on narrative therapy, recovery and psychoeducation which was specially tailored for this population by the authors. the sample corresponds to 76 individuals with a severe mental illness (icd-10), currently treated in the two participating community mental health centers (cosam). the category "severe mental illness" includes patients with diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder and severe depressive disorder with psychotic symptoms. finally, those two clinics were chosen by convenience in order to facilitate the implementation of this study. before and after the intervention, the participants' self-stigma (internalized stigma of mental illness, ismi), treatment adherence (weeks in treatment), and quality of life (sevilla quality of life scale) were measured. in addition, the following control variables were also evaluated, due to their influence on the principal outcomes: 1) sociodemographic information, 2) symptom presence and severity (positive and negative syndrome scale, panss), and 3) alcohol consumption (the alcohol use disorders identification test, audit).

Eligibility criteria:
inclusion criteria: * people with diagnosis of severe mental illness, including the following icd-10 disorders: schizophrenia, schizoaffective disorder, bipolar disorder, severe depressive episode with psychotic symptoms. * no longer than 5 years since the diagnosis since the first visit to a mental health clinic. exclusion criteria: * expressing active suicidal ideation. * having substance abuse or dependence alone (may have psychotic symptoms but does not meet criteria for diagnoses included). * presenting cognitive or other sensorial impairment which is likely to preclude reliable assessment via our interview procedures

Keywords: stigma psychosocial intervention low-and-middle income countries
the effect of individualized exercise guidance on pregnancy outcome

Conditions: Pregnancy Outcome; Gestational Weight Gain; Mediation; Macrosomia, Fetal

Summary: a single center, randomized controlled trial was conducted to investigate whether individualized exercise guidance was more effective in improving pregnancy outcomes in normal pregnant women. what's more, the trial was also conducted to find out whether there is a mediating effect between prenatal exercise and pregnancy outcomes.

fetal macrosomia refers to newborns with a birth weight more than 4000 grams, which poses varying degrees of risks to the health of both mother and infant and also affects the health outcomes of future generations. research has found that exercise can effectively reduce the incidence of macrosomia and prevent gestational diabetes mellitus, pregnancy-induced hypertension, and excessive weight gain during pregnancy. however, every pregnant woman's individual situation and exercise habits are different, and personalized guidance based on their own circumstances is necessary during pregnancy exercise. the use of intelligent devices for supervision and management is also essential. to explore the impact of personalized exercise guidance during pregnancy on macrosomia, as well as the mediating effect of weight gain during pregnancy on exercise and macrosomia, we conducted a prospective randomized controlled clinical trial. the study included pregnant women who were over 20 years old, married, singleton, in the mid-term of pregnancy, and had no contraindications for exercise during pregnancy. they were randomly divided into an individualized exercise guidance group and standard clinic prenatal care group. both groups received routine prenatal care and did not have any special dietary recommendations. the pregnant women in the individualized exercise guidance group received regular exercise guidance from a professional teacher and were supervised and managed through a wechat group. the main outcome indicators were the incidence of macrosomia and the total weight gain during pregnancy.

Eligibility criteria:
inclusion criteria: * aged between 18 and 45 years. * with singleton pregnancy. * second trimester. * no contraindications to exercise during pregnancy. * be able to use smart phone for chatting, read and write basic chinese. * volunteer for research. exclusion criteria: * adverse pregnancy reaction, such as abdominal pain, vaginal bleeding and so on.